[ad_1]
Oncternal Therapeutics (NASDAQ:ONCT) traded lower on Tuesday after announcing initial results from its Phase 1/2 study for autologous CAR T cell therapy, ONCT-808-101, in patients with B-cell lymphoma, a cancer affecting the immune system.
Citing data from three patients who received initial dosing, San Diego, California-based Oncternal (ONCT) said that two achieved a complete metabolic response, while the third achieved a partial response.
The dose escalation/dose expansion trial was designed to evaluate ONCT-808-101 in patients with relapsed or refractory aggressive B-cell lymphoma who have failed in prior CD19-targeted CAR T therapy.
However, the readout indicated a Grade 5 (fatal) serious adverse event in a patient who received the second dose level of 3×106 CAR T cells per kg. The 80-year-old subject had received four previous lines of therapy.
Oncternal (ONCT) also said that the FDA has greenlighted several changes to the trial, including modifications to eligibility criteria and a plan to test lower doses for future patients.
“With this clear path forward, we plan to implement the protocol amendment as rapidly as possible,” Chief Medical Officer Salim Yazji noted.
More on Oncternal Therapeutics
[ad_2]